Alanine for Immune Function

Immune cells — lymphocytes, macrophages, neutrophils, and dendritic cells — are among the most metabolically active cells in the body, with energy and biosynthetic demands that rival those of skeletal muscle and exceed those of most other tissue types. The classic work of Eric Newsholme and his Oxford collaborators in the 1980s established that activated lymphocytes consume glutamine at extraordinary rates and excrete the nitrogen as alanine in a tightly coupled glutamine-alanine relay. The same circuitry was later shown to underlie immune cell function in sepsis, trauma, major surgery, and critical illness — conditions in which the body's endogenous glutamine pool is consumed faster than the muscle can synthesize it, and clinical outcomes deteriorate as the relay fails. This is the biochemical foundation of the modern intravenous alanine-glutamine dipeptide (Dipeptiven) used in critical-care parenteral nutrition. This page traces the biochemistry of immune-cell amino acid metabolism, the glutamine-alanine relay, the concept of conditional essentiality during critical illness, and the practical clinical applications of amino-acid support in immunocompromised patients.

Immune Cells as Metabolically Demanding Tissue
The Glutamine-Alanine Relay Inside Immune Cells
Alanine and Lymphocyte Proliferation
Conditional Essentiality During Critical Illness
Sepsis and Critical Care Nutrition
The Alanine-Glutamine Dipeptide (Dipeptiven)
Exercise-Induced Transient Immunosuppression
Wound Healing and Post-Surgical Recovery
Gut Barrier Function and Mucosal Immunity
Cautions (Including the REDOXS Critical-Care Signal)
Key Research Papers
Connections

Immune Cells as Metabolically Demanding Tissue

An activated T lymphocyte is one of the most metabolically active cells in the body. When a naive T cell encounters antigen and undergoes clonal expansion, it goes from a quiescent doubling time of months (or never, in a true naive cell) to a doubling time of approximately 6-12 hours. This requires building a complete new daughter cell — all of its proteins, lipids, nucleic acids, and organelles — from scratch in less than half a day. The metabolic demand for substrate is enormous and the substrate requirements are highly amino-acid-skewed.

The Newsholme group's seminal experiments in the 1980s measured the rates at which different amino acids are consumed by activated lymphocytes. Two amino acids stand out:

Glutamine — consumed at rates 10-100 times higher than any other amino acid. Lymphocytes use glutamine for energy production (via glutaminolysis, the conversion of glutamine to glutamate to alpha-ketoglutarate to the TCA cycle), for nucleotide biosynthesis (the amino group of glutamine donates to purine and pyrimidine synthesis), and for redox homeostasis (the glutathione precursor cysteine is in part regenerated from glutamine-derived carbon).
Glucose — consumed at high rates via glycolysis, primarily for ribose-5-phosphate production in the pentose phosphate pathway (also for nucleotide synthesis) and for anabolic biosynthesis of fatty acids and cholesterol.

The combination of high glutamine and glucose consumption is sometimes called the "Warburg-like" phenotype of activated immune cells (after the German biochemist Otto Warburg, who first described the same metabolic phenotype in tumor cells). The two cell populations share a fundamental biochemical strategy: maximize biosynthetic substrate availability at the expense of complete oxidation, with the metabolic cost paid by elevated glycolytic and glutaminolytic flux.

The dependence on glutamine is so extreme that immune function collapses if glutamine is depleted. In vitro, removing glutamine from culture media stops lymphocyte proliferation, IL-2 production, and antibody secretion within hours. In vivo, the body normally maintains plasma glutamine concentrations of 500-800 micromolar — the highest of any amino acid — specifically to ensure that immune cells have access to this critical substrate even during fasting and stress.

Back to Table of Contents

The Glutamine-Alanine Relay Inside Immune Cells

Here is where alanine enters the immune story. When activated lymphocytes consume glutamine, they do not fully oxidize it. The reaction proceeds as follows:

Glutamine enters the cell via the ASCT2 transporter (SLC1A5), one of the highest-expression amino acid transporters on activated lymphocytes.
Glutaminase converts glutamine to glutamate, releasing ammonia as a byproduct.
Glutamate is transaminated to alpha-ketoglutarate, donating its amino group either to pyruvate (forming alanine via ALT) or to oxaloacetate (forming aspartate via AST).
Alpha-ketoglutarate enters the TCA cycle, where it is partially oxidized for ATP production.
The TCA intermediates are siphoned off for biosynthesis — citrate exits the mitochondria to support fatty acid synthesis, oxaloacetate provides aspartate for nucleotide synthesis, alpha-ketoglutarate provides 2-hydroxyglutarate and succinate for epigenetic modification of transcription factors.
Alanine (and lactate) are excreted as the metabolic end products. Alanine carries away one nitrogen per glutamine consumed; lactate carries away the partially-oxidized carbon when glycolytic flux exceeds the TCA cycle's capacity to accept pyruvate.

This is the glutamine-alanine relay: the cell consumes glutamine, uses its carbon and nitrogen for biosynthesis, and exports the metabolic waste nitrogen as alanine. The relay is quantitatively important — activated lymphocytes can excrete alanine at rates similar to their glutamine uptake rates. The exported alanine returns to the liver and feeds the same hepatic gluconeogenic and urea-cycle disposal pathway that handles muscle-derived alanine (see the companion Gluconeogenesis page).

The implication is that alanine and glutamine are not independent variables in immune physiology — they are coupled inputs and outputs of the same lymphocyte metabolic engine. Therapeutic strategies that target immune function through amino acid supplementation must consider the pair together, which is why modern parenteral nutrition for immune compromise uses alanine-glutamine dipeptides rather than glutamine alone (see Dipeptiven section below).

Back to Table of Contents

Alanine and Lymphocyte Proliferation

The direct role of alanine in lymphocyte proliferation is more limited than that of glutamine, but several specific contributions matter:

Alanine is a non-essential substrate for protein synthesis. Roughly 8% of the amino acid residues in human proteins are alanine, so the daughter lymphocyte built during a 6-12 hour proliferation cycle requires alanine for its protein content. While alanine can be synthesized de novo from pyruvate plus a nitrogen donor, the de novo synthesis costs ATP and competes with the nitrogen demands elsewhere in the cell. Exogenous alanine availability spares this biosynthetic burden.
Alanine is required for the alanine-aspartate-glutamate axis that feeds purine and pyrimidine synthesis. Aspartate (donated by AST transamination from glutamate) provides nitrogen atoms for both adenine and thymidine; glutamate (donated by glutamine deamidation) provides nitrogen for both guanine and cytosine. The transamination flux through ALT helps maintain the cytosolic alanine-pyruvate balance that keeps this axis running.
Alanine in the immunological synapse — the contact zone between an antigen-presenting cell and a T cell. Local amino acid concentrations in the immunological synapse modulate signaling through the mTORC1 nutrient-sensing pathway. mTORC1 integrates amino acid availability, growth factor signaling, and cellular energy status to license clonal expansion. Severe amino acid deprivation (including alanine) inactivates mTORC1 and blocks T cell proliferation.
The mTORC1 pathway is also sensitive to the alanine sensor SAR1B in some cell types, though the lymphocyte-specific significance is still being characterized.

The clinical implication is that severe protein malnutrition impairs lymphocyte proliferation. Patients with kwashiorkor (protein malnutrition with caloric adequacy) and marasmus (combined protein-calorie malnutrition) exhibit profound lymphopenia and reduced T-cell mitogen responsiveness, with secondary increases in opportunistic infection rates. The reciprocal observation — that nutritional repletion restores T-cell function — is the basis for the modern emphasis on adequate enteral and parenteral amino acid provision in hospitalized patients.

For patients in the developed world, frank protein malnutrition is rare but subclinical inadequacy is common in elderly patients, patients with chronic illness, and patients who have recently undergone major surgery. Each of these populations shows reduced immune function that improves with amino acid supplementation.

Back to Table of Contents

Conditional Essentiality During Critical Illness

Alanine is conventionally classified as a non-essential amino acid — the body can synthesize it from pyruvate plus a nitrogen donor, so dietary intake is not strictly required. However, the concept of conditional essentiality applies: under certain pathological states, endogenous synthesis cannot keep up with demand and exogenous supply becomes necessary for normal physiological function.

Glutamine is the canonical conditionally essential amino acid — well-established to drop precipitously in critical illness, with associated mortality. Alanine's conditional essentiality status is less well-defined but is increasingly recognized in several specific clinical settings:

Sepsis — plasma alanine paradoxically remains stable or even rises early in sepsis (due to accelerated muscle catabolism), but tissue-specific alanine availability in the liver and immune compartments becomes inadequate as the cytokine storm and inflammatory state proceed. The hepatic gluconeogenic demand exceeds the alanine supply, contributing to the lactic acidosis of severe sepsis.
Major trauma — the catabolic response to multiple injury creates a large nitrogen-disposal load that exceeds normal alanine shuttle capacity. Plasma alanine can rise to 600-800 micromolar transiently as the muscle exports nitrogen faster than the liver can clear it.
Burns — the largest sustained hypermetabolic state in clinical medicine. A patient with 40% total body surface area burns can sustain resting metabolic rates of 200% of predicted for weeks. Alanine flux becomes a major nutritional consideration.
Liver failure — the alanine cycle collapses from the liver-failure side rather than the muscle side. Plasma alanine rises sharply because the liver cannot clear it, but the cycle no longer delivers useful glucose or safely disposed nitrogen. BCAA-enriched formulations support muscle alanine synthesis without overloading the failing liver.
Cancer cachexia — the cachectic muscle loss in advanced cancer reflects a sustained shift to net catabolism, with alanine flux elevated for months on end. Nutritional intervention with full amino acid replacement remains controversial as it may also feed the tumor.

The practical clinical inference is that critical illness requires aggressive nutritional support of the amino acid pool, with formulations that provide complete coverage of both essential and conditionally essential amino acids. The trend in modern critical care nutrition has been toward earlier enteral feeding, more complete amino acid profiles, and targeted use of alanine-glutamine dipeptides for the sickest patients.

Back to Table of Contents

Sepsis and Critical Care Nutrition

The metabolic state of sepsis is biochemically distinctive: a hypermetabolic, hypercatabolic, insulin-resistant state in which the body is simultaneously trying to fuel an enormous immune response while losing the ability to use its conventional energy substrates efficiently. Several specific features matter for the alanine story:

Skeletal muscle proteolysis accelerates — net muscle protein breakdown can exceed 100 g/day in severe sepsis, releasing branched-chain amino acids, alanine, and glutamine into the circulation.
Insulin resistance develops — cytokines (TNF-alpha, IL-6, IL-1) impair muscle glucose uptake. Hyperglycemia coexists with elevated lactate (the lactate-pyruvate ratio rises).
Plasma glutamine drops — this is one of the most reliable metabolic markers of severe sepsis. Normal plasma glutamine 500-800 micromolar drops to 200-400 micromolar in severe sepsis. The drop reflects consumption by activated immune cells outstripping muscle synthesis.
Plasma alanine paradoxically may rise early then fall — reflecting first the proteolytic phase then the failure-to-clear phase as multi-organ dysfunction develops.
Hepatic gluconeogenesis from alanine is impaired — both because of relative substrate insufficiency and because cytokine-mediated hepatic dysfunction reduces gluconeogenic enzyme activity. The resulting glucose-lactate-alanine imbalance contributes to the lactic acidosis that prognosticates severe sepsis.

Modern critical care nutrition guidelines (the ASPEN/SCCM 2016 update and the ESPEN 2019 guidelines) emphasize:

Early enteral nutrition (within 24-48 hours of ICU admission) whenever feasible
Adequate protein provision (1.2-2.0 g/kg/day in critical illness, higher than the 0.8 g/kg/day RDA for healthy adults)
Selective use of supplemental glutamine in burn patients and patients with major trauma (the ESPEN guideline)
Caution against supplemental glutamine in patients with multi-organ failure (the REDOXS trial signal — see Cautions section)

The era of high-dose glutamine supplementation for all critically ill patients has ended; modern practice individualizes the approach based on illness severity and organ function. Alanine-glutamine dipeptide formulations (Dipeptiven) remain in use in many European intensive care units but are less commonly used in North America.

Back to Table of Contents

The Alanine-Glutamine Dipeptide (Dipeptiven)

Free L-glutamine in solution is unstable — it spontaneously degrades to pyroglutamate and ammonia at a rate that increases with temperature and pH. This makes pure glutamine difficult to formulate for parenteral administration: a TPN bag containing free glutamine would generate substantial ammonia by the end of the infusion. The pharmaceutical solution to this problem is to use a dipeptide form — L-alanyl-L-glutamine — which is heat-stable, soluble at high concentration, and rapidly cleaved by plasma and tissue dipeptidases to release free glutamine and free alanine after infusion.

The branded preparation Dipeptiven (Fresenius Kabi) contains 20 g of L-alanyl-L-glutamine per 100 mL, corresponding to 13.5 g of free glutamine plus 8.2 g of free alanine after enzymatic cleavage. The typical clinical dose is 1.5-2.0 mL/kg/day added to standard parenteral nutrition, providing approximately 0.3-0.4 g/kg/day of L-glutamine equivalent.

The clinical rationale combines two effects:

Replenishes the depleted glutamine pool during critical illness, supporting immune cell function, gut barrier integrity, and antioxidant capacity (glutamine is a glutathione precursor).
Provides the alanine partner for the glutamine-alanine relay, ensuring that the metabolic engine has both inputs and a viable nitrogen-export route. This is a more theoretical benefit but underlies the formulation choice.

The clinical evidence for Dipeptiven is mixed. Several meta-analyses (Wischmeyer 2014, Bollhalder 2013) found modest reductions in infectious complications and length of stay in surgical and trauma patients. The 2013 REDOXS trial in patients with multi-organ failure found increased mortality with high-dose glutamine, raising concerns about routine use in the sickest patients. Current practice in Europe favors Dipeptiven for patients with severe trauma, burns, and abdominal surgery; in North America, the same formulation is less commonly used and many ICU teams have moved toward enteral immunonutrition formulas instead.

For non-ICU oral alanine-glutamine support, the dipeptide form has limited bioavailability advantage over free amino acids (the gut breaks both down before absorption). Oral L-alanine and L-glutamine sold separately as nutritional supplements perform similarly to combined dipeptide formulations for the rare indications where they are used.

Back to Table of Contents

Exercise-Induced Transient Immunosuppression

Heavy endurance exercise produces a transient immunosuppressive state in the hours following the workout, characterized by reduced natural killer cell activity, reduced salivary IgA secretion, and elevated risk of upper respiratory tract infection. The phenomenon is well documented in marathon runners, ultra-endurance athletes, and high-volume training in Olympic-level swimmers and rowers. The mechanism is multifactorial, but amino acid shifts contribute meaningfully:

Plasma glutamine falls after heavy endurance exercise — from a baseline of 600 micromolar to 400-500 micromolar after a marathon, and the decline persists for hours. The drop has been hypothesized to contribute to the post-exercise immunosuppression by depriving lymphocytes of their preferred substrate. This is the basis for the "glutamine hypothesis" of exercise immunology popularized by Newsholme in the 1990s.
Plasma alanine peaks during exercise and falls post-exercise — mirroring the glutamine shift. The alanine pool is being mobilized for hepatic gluconeogenesis during the workout and then is replenished from muscle protein breakdown during recovery.
The glutamine hypothesis has been partially walked back — subsequent intervention trials with oral glutamine supplementation in endurance athletes have shown only modest effects on immune markers and no consistent reduction in upper respiratory infection rates. The mechanism is more complex than substrate depletion alone (cortisol, beta-adrenergic activation, and direct exercise-induced lymphocyte apoptosis all contribute).
Practical implications — endurance athletes are still well-advised to maintain adequate protein intake (1.2-1.6 g/kg/day for active individuals) and to consume a recovery meal containing both protein and carbohydrate within 1-2 hours of completing a heavy session. Whether dedicated glutamine or alanine-glutamine supplementation provides additional benefit remains unclear; the modest cost and excellent safety profile mean some athletes use them prophylactically without strong evidence.

Back to Table of Contents

Wound Healing and Post-Surgical Recovery

Tissue repair after surgery, trauma, or burn injury depends on the rapid proliferation of multiple cell types — fibroblasts depositing collagen, endothelial cells building new capillaries, keratinocytes migrating to close the wound, and immune cells mounting the inflammatory and remodeling response. All of these cell populations share the metabolic profile of activated immune cells: high glutamine and glucose consumption, elevated alanine output, and dependence on adequate amino acid supply.

The clinical correlate is that protein-malnourished patients heal wounds slowly and have higher rates of wound dehiscence, surgical site infection, and anastomotic leak. Modern preoperative nutritional optimization (the "prehab" approach used in major colorectal and pancreatic surgery) emphasizes:

Preoperative protein supplementation (1.2-1.5 g/kg/day) for 2-4 weeks before elective surgery
Carbohydrate loading the night before and the morning of surgery (when not contraindicated)
Early postoperative enteral nutrition (within 24 hours)
Selective use of immunonutrition formulas (containing arginine, omega-3 fatty acids, and nucleotides) in high-risk surgical patients

For more on wound healing nutrition, see our pages on Glutamine and Arginine.

Back to Table of Contents

Gut Barrier Function and Mucosal Immunity

The small intestinal enterocyte is one of the most glutamine-dependent cells in the body, and it shares the alanine-export pattern of activated lymphocytes. Enterocytes consume approximately 30% of total dietary glutamine on the first pass, using it for energy (the small intestine uses glutamine as its preferred fuel, ahead of glucose) and for nucleotide synthesis (the small intestinal epithelium turns over completely every 3-5 days, requiring continuous DNA synthesis). The metabolic waste is excreted as alanine into the portal circulation.

This is the biochemical basis for the well-documented gut-barrier failure that occurs during prolonged fasting, parenteral nutrition without enteral support, and critical illness. When the enterocyte glutamine supply fails, the tight junctions between enterocytes become leaky, bacterial translocation across the gut wall increases, and the gut becomes a source of inflammation and infection. This phenomenon — sometimes called "the gut as the motor of multi-organ failure" — underlies the modern emphasis on early enteral nutrition in the ICU even when parenteral nutrition is also being given.

The clinical implication is that gut barrier integrity depends on adequate luminal substrate, with glutamine being the most important substrate and alanine being the secondary export. Patients who must remain NPO for extended periods (severe pancreatitis, post-bariatric leaks, complex gut surgery) benefit from trophic enteral feeding (small-volume drip feeds of formula directly into the small intestine) even when calorically inadequate, simply to maintain the gut barrier function that the enterocytes provide.

Back to Table of Contents

Cautions (Including the REDOXS Critical-Care Signal)

REDOXS trial signal in critical illness — the 2013 NEJM REDOXS trial (Heyland et al.) randomized 1,223 critically ill patients with multi-organ failure to high-dose glutamine plus antioxidants vs placebo. The trial was stopped early due to a signal of increased mortality in the glutamine arm (32.4% vs 27.2% placebo, p=0.05). The mechanism is debated but may relate to amino acid loading in patients with severe renal and hepatic dysfunction. The signal has substantially cooled enthusiasm for routine glutamine supplementation in the sickest ICU patients in North America. Glutamine remains in use for burns, trauma, and abdominal surgery (where the evidence is more favorable) but is no longer recommended for multi-organ failure.
Chronic kidney disease — advanced CKD limits the capacity to handle nitrogen loads. Amino acid supplementation (including alanine and glutamine) should be conservative and renal-failure-specific essential amino acid formulations are preferred.
Hepatic encephalopathy — patients with cirrhotic encephalopathy should not receive supplemental aromatic amino acids or methionine. Branched-chain amino acid-enriched formulations are preferred. Routine alanine supplementation is not indicated.
Cancer cachexia — the balance between nourishing the patient and feeding the tumor is complex. Amino acid supplementation in advanced cancer should be guided by an experienced oncology dietitian rather than by general principles.
Inborn errors of urea cycle — carbamoyl phosphate synthetase deficiency, ornithine transcarbamylase deficiency, and similar disorders impair nitrogen disposal. High-protein meals or amino acid supplements trigger acute hyperammonemia. Protein restriction is the standard management.
Healthy adults — the clinical applications of alanine for immune function in well-nourished healthy adults are limited. The conditions where alanine genuinely helps immune function (severe protein malnutrition, sepsis, burns) are mostly inpatient settings requiring physician supervision. Routine over-the-counter alanine supplementation for "immune support" in otherwise healthy adults is not supported by the evidence and is not generally recommended.
Pregnant and lactating women — standard prenatal nutrition with adequate dietary protein provides sufficient alanine. Targeted supplementation is not indicated in the absence of specific medical guidance.

Back to Table of Contents

Key Research Papers

Newsholme P, Curi R, Pithon-Curi TC, et al. (1999). Glutamine metabolism by lymphocytes, macrophages, and neutrophils: its importance in health and disease. Journal of Nutritional Biochemistry 10(6):316-324. — DOI: 10.1016/S0955-2863(99)00045-7
Newsholme EA, Crabtree B, Ardawi MS (1985). Glutamine metabolism in lymphocytes: its biochemical, physiological, and clinical importance. Quarterly Journal of Experimental Physiology 70(4):473-489. — PubMed
Wischmeyer PE (2008). Glutamine: mode of action in critical illness. Critical Care Medicine 36(9 Suppl):S541-S544. — DOI: 10.1097/CCM.0b013e318168ec55
Heyland DK, Dhaliwal R, Day AG, et al. (2013). A Randomized Trial of Glutamine and Antioxidants in Critically Ill Patients (REDOXS). NEJM 368(16):1489-1497. — DOI: 10.1056/NEJMoa1212722
Calder PC (2006). Branched-chain amino acids and immunity. Journal of Nutrition 136(1 Suppl):288S-293S. — DOI: 10.1093/jn/136.1.288S
Wischmeyer PE, Dhaliwal R, McCall M, Ziegler TR, Heyland DK (2014). Parenteral glutamine supplementation in critical illness: a systematic review. Critical Care 18(2):R76. — DOI: 10.1186/cc13836
Mittendorfer B, Volpi E, Wolfe RR (2001). Whole body and skeletal muscle glutamine metabolism in healthy subjects. American Journal of Physiology-Endocrinology and Metabolism 280(2):E323-E333. — DOI: 10.1152/ajpendo.2001.280.2.E323
Karinch AM, Pan M, Lin CM, Strange R, Souba WW (2001). Glutamine metabolism in sepsis and infection. Journal of Nutrition 131(9 Suppl):2535S-2538S. — DOI: 10.1093/jn/131.9.2535S
Curi R, Newsholme P, Procopio J, et al. (2007). Glutamine, gene expression, and cell function. Frontiers in Bioscience 12:344-357. — DOI: 10.2741/2197
Bollhalder L, Pfeil AM, Tomonaga Y, Schwenkglenks M (2013). A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clinical Nutrition 32(2):213-223. — DOI: 10.1016/j.clnu.2012.11.003
Stehle P, Ellger B, Kojic D, et al. (2017). Glutamine dipeptide-supplemented parenteral nutrition improves outcomes in critically ill patients: meta-analysis. Clinical Nutrition ESPEN 17:75-85. — DOI: 10.1016/j.clnesp.2016.09.007
Singer P, Blaser AR, Berger MM, et al. (2019). ESPEN guideline on clinical nutrition in the intensive care unit. Clinical Nutrition 38(1):48-79. — DOI: 10.1016/j.clnu.2018.08.037
Reeds PJ, Burrin DG (2001). Glutamine and the bowel. Journal of Nutrition 131(9 Suppl):2505S-2508S. — DOI: 10.1093/jn/131.9.2505S

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents